Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 315

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 315
---
 
  63 |
|:------------------------|:--|:-------|----:|
| 2026                    |   | ​      |  63 |
| 2027                    |   | ​      |  63 |
| 2028                    |   | ​      |  63 |
| 2029                    |   | ​      |  63 |
| Thereafter              |   | ​      |  70 |
| Total                   | ​ | $      | 385 |

The Company recognized less than $ million for amortization expense for each of the years ended December 31, 2024 and 2023. Amortization expense is included in research and development expense in the statements of operations.

F-17

6.Accrued Expenses

Accrued expenses consisted of the following as of December 31, 2024 and 2023 (in thousands):

| ​                                          
 ​                                          | ​ 
 ​ | ​                  
 As of December 31, |     ​ 
  2024 | ​ | ​ |     ​ 
  2023 |
|:-------------------------------------------|:--|:-------------------|------:|:--|:--|------:|
| Accrued research and development expenses  | ​ | $                  | 5,172 | ​ | $ |   518 |
| Accrued employee compensation and benefits | ​ |                    | 1,142 | ​ |   |   942 |
| Accrued professional fees                  | ​ |                    | 1,756 | ​ |   |   108 |
| Other accrued expenses                     | ​ |                    |     8 | ​ |   |     9 |
| Total accrued expenses                     | ​ | $                  | 8,078 | ​ | $ | 1,577 |

7.Leases

The Company has operating lease pertaining to square feet of corporate office space in Sugar Land, Texas pursuant to a lease agreement that commenced April 1, 2022. As of December 31, 2024 the remaining term of lease was years. The lease requires monthly lease payments that are subject to annual increases throughout the lease term.

The components of lease costs, which are included within general and administrative expenses in the Company’s statements of operations were as follows (in thousands):

| ​                    
 ​                    | ​ |                  ​ 
 For the Year Ended |   ​ | ​ |    ​ |   ​ |
|:---------------------|:--|-------------------